Back

One-year cardiovascular outcomes before and after GLP-1 ra discontinuation: a real-world retrospective cohort study

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Prognostic factors and outcomes in chronic coronary syndromes Epidemiology, Prognosis, Outcome ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Associate Professor Andreas Kalogeropoulos

Stony Brook University, Stony Brook (United States of America)

5 More presentations in this session

Presentation thumbnail
Clinical and economic burden of patients with and without myocardial infarction: a contemporary nationwide 10-year registry comparison
Doctor C. Reitan (Stockholm, SE)
Abstract Slides Video
Presentation thumbnail
Interleukin-1B and ST2L/IL-33R and risk of clinical outcomes in patients with multi-vessel disease
Doctor J. Li (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
Long-term prognostic impact of remnant cholesterol distribution after percutaneous coronary intervention and coronary artery bypass graft: insights from a nationwide cohort
Associate Professor J. Lee (Wonju, KR)
Abstract Slides Video
Presentation thumbnail
Impact of growing up in a low-income household on midlife coronary atherosclerosis
Doctor S. Herlitz (Stockholm, SE)
Abstract Slides Video
Presentation thumbnail
Declining rates of out-of-hospital-cardiac arrest among individuals with ischemic heart disease
Mr C. Hansen (Copenhagen, DK)
Abstract Slides Video

Access the full session

Session thumbnail
Prognostic factors and outcomes in chronic coronary syndromes
Video

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Session
What's new for GLP-1 agonist and SGLT2 inhibitor cardiovascular pharmacotherapy?
thumbnail
Congress Session
Late-Breaking Clinical Science: cardiometabolic medicine
thumbnail
Congress Presentation
Cardiovascular outcomes in sustained use of glucagon like peptide inhibitors: a trial inspired population vs. a broad population

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources